Literature DB >> 11176040

Her2 and trastuzumab in breast cancer.

J Horton1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11176040     DOI: 10.1177/107327480100800113

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


× No keyword cloud information.
  5 in total

1.  Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.

Authors:  Sangjung Park; Hye-Young Wang; Sunghyun Kim; Sungwoo Ahn; Dongsup Lee; Yoonjung Cho; Kwang Hwa Park; Dongju Jung; Seung Il Kim; Hyeyoung Lee
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

Review 2.  Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

Authors:  Kate McKeage; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.

Authors:  Kristin McLarty; Bart Cornelissen; Deborah A Scollard; Susan J Done; Kathy Chun; Raymond M Reilly
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-19       Impact factor: 9.236

4.  Colorimetric immunoassay for detection of tumor markers.

Authors:  Yongmei Yin; Ya Cao; Yuanyuan Xu; Genxi Li
Journal:  Int J Mol Sci       Date:  2010-12-07       Impact factor: 5.923

5.  Lead sulfide near-infrared quantum dot bioconjugates for targeted molecular imaging.

Authors:  Jiantang Sun; Ming-Qiang Zhu; Kun Fu; Nastassja Lewinski; Rebekah A Drezek
Journal:  Int J Nanomedicine       Date:  2007
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.